Board of Directors

    Global products demand rigor and foresight in every aspect of their business. INT’s board of directors are leaders in supply chain management, manufacturing, intellectual property, and research.


    Kim has over 30 years of medical device commercial experience in multinational and start-up companies. She spent 16 years with Boehringer Mannheim/Roche Diagnostics where she held multiple positions in sales and marketing including P&L responsibility for the Diabetes Care and Point of Care diagnostics businesses. The balance of her career has been dedicated to leading start-up medical device organizations including BioStar, Inc. (infectious disease diagnostics), Medingo, Ltd, Anodyne Therapy, GlycoMark, and most recently was President of DYSIS Medical, Inc., a UK-based women’s health device manufacturer.  Kim has mentored companies and people as Director of Mentoring for the Healthcare Businesswomen’s Association, Co-Chair of Health Tech for the Florida Israel Business Accelerator and Mentor for the Tampa Bay WAVE Tech Accelerator. In 2015, she earned recognition as the Tampa Bay Businesswoman of the Year in the Health and Wellness category. She brings a broad understanding of medical device sales, marketing, regulatory compliance, reimbursement, and distribution in all healthcare markets including hospitals, integrated networks, physicians, home health, long term care, retail, and managed care. Kim received her BS in Biology from St. Lawrence University and completed graduate work in business management at Arizona State University, Columbia University, and the International Institute of Management Development in Lausanne, Switzerland.


    Noel is currently CEO of Epigenomics, Inc., a leader in blood-based screening for colon cancer.

    Earlier in his career he worked at Gilford Instruments which was acquired and became Ciba Corning, serving in multiple leadership positions within the commercial and strategic organizations in blood chemistry. His last role was in POC as leader of the BioTrack POC coagulation efforts. He assumed the lead commercial leadership role at BioStar, a point-of-care infectious pathogen assay company. The company was acquired by Thermo Electron, where Noel served as CEO of BioStar and led all strategic efforts for clinical chemistry and pathology for Thermo. In 2004, he moved into the Molecular Diagnostic field as SVP at Qiagen for molecular diagnostics, leading the transition from sample prep to assay products. Later he led the diagnostic efforts at Affymetrix by completing multiple cancer assays development deals. He then became CEO of Opgen, Inc., a genome assembly company. He served as a commercial advisor to Sequenta before their acquisition by Adaptive Biotechnology, a market expert for Price Waterhouse Cooper and is an industry advisor to DDN News. He received his undergraduate degrees from West Virginia University where he was Phi Beta Kappa in both chemistry and biology. He completed graduate work at Georgetown University in biochemistry and in entrepreneurship at Case Western University.


    Hideki Itaya currently serves as Division Manager at Enplas Corporation. Prior to his current role, Hideki worked at Single Cell Technology, an Enplas subsidiary focused on therapeutic antibody development, first as Director of Sales and Marketing and then as Vice President. Hideki also worked at Affymetrix, Japan, first serving as Sales Director and then as General Manager.  Prior to his work at Affymetrix, Hideki enjoyed a productive career at Hitachi Chemical Co. Hideki started his Hitachi Chemical tenure as a Researcher and then assumed a Product Manager role at MAST Immunosystems, developing the Japanese market for in vitro diagnostics for allergy testing. Upon the acquisition of MAST by Hitachi, Hideki moved to the US site, initially to direct manufacturing and then served as Vice President of Operations, developed a fully-automated instrument, and then as Vice President of Sales with a focus on the US physician’s office lab market. In 2008, Hideki returned to Hitachi Chemical, Japan, and held several key leadership positions, eventually managing the New Business Division including the CTC (circulating tumor cell) detection system.  Hideki holds a bachelor’s degree in Chemical Engineering from Waseda University, Tokyo, Japan.

    Ragu Raman
    Ragu Raman is the President and Chief Executive Officer of INT, responsible for all corporate functions. Before joining INT, Mr. Raman worked at Ortho Clinical Diagnostics for five years, most recently as the Head of R&D for Instrument Platforms addressing Clinical Labs & Transfusion Medicine. In this role, he was responsible for leading the technology strategy, product development, and continuous improvements.  Prior to joining Ortho, Mr. Raman was the Vice President of R&D at STERIS Corporation for Infection Prevention Technologies serving the Healthcare and Life Science business segments. Mr. Raman also has served as R&D Director at Philips Healthcare in the CT Imaging Systems business, where he led Systems Engineering and Gantry / X-Ray subsystems development. Mr. Raman also served in multiple positions within GE Healthcare Interventional Cardiology, Surgery, and Digital Radiology businesses. Mr. Raman has a Bachelors in Engineering from the Birla Institute of Technology & Science, India, and a Master's in Software Engineering from Kansas State University.

    Michael is Chief Innovation Officer of INT. He has a PhD in molecular biology from Northwestern University and completed a post-doctoral fellowship in the Department of Microbiology at the University of Illinois Medical Center. After completing his JD at Cornell University, he practiced as a patent attorney at Nixon Peabody, LLP in Rochester. While at Nixon Peabody, he played a significant role in developing the licensing strategy for a major genetic sequencing enterprise, as well as patenting and licensing technologies for several other companies and universities.


    Dr. David R. Franz served in the U.S. Army Medical Research and Materiel Command for 23 of 27 years on active duty and retired as Colonel.  He served as Commander of the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and as Deputy Commander of the Medical Research and Materiel Command.  Prior to joining the Command, he served as group veterinarian for the 10th Special Forces Group (Airborne). He was chief inspector on three United Nations Special Commission biological warfare inspection missions to Iraq and a technical advisor on long-term monitoring. He also served as a member of the first two U.S.-U.K. teams that visited Russia in support of the Trilateral Joint Statement on Biological Weapons and as a member of the Trilateral Experts' Committee for biological weapons negotiations. His current activities include the role of international engagement in public health and the life sciences as a component of global security policy.  Domestically he encourages thoughtfulness when regulating life-sciences research in the name of security, thereby minimizing negative impact on progress in the life sciences.  Dr. Franz earned a DVM from Kansas State University and a PhD in Physiology from Baylor College of Medicine. 


    John Hamre is currently president and CEO of the Center for Strategic and International Studies (CSIS). Before joining CSIS, Dr. Hamre held several leadership positions in the Department of Defense, having served as the 26th U.S. Deputy Secretary of Defense as well as serving as the Under Secretary of Defense (Comptroller) where he was the principal assistant to the Secretary of Defense for the preparation, presentation, and execution of the defense budget and management improvement programs. Additionally, Dr. Hamre was appointed serve as chairman of the Defense Policy Board. Before serving in the Department of Defense, Dr. Hamre worked for 10 years as a professional staff member of the Senate Armed Services Committee. During that time, he was primarily responsible for the oversight and evaluation of procurement, research, and development programs, defense budget issues, and relations with the Senate Appropriations Committee. From 1978 to 1984, Dr. Hamre served in the Congressional Budget Office, where he became its deputy assistant director for national security and international affairs. In that position, he oversaw analysis and other support for committees in both the House of Representatives and the Senate. Dr. Hamre received his PhD, with distinction, from the School of Advanced International Studies at Johns Hopkins University in Washington, D.C., where his studies focused on international politics and economics and U.S. foreign policy. He also received his BA, with high distinction, from Augustana College in Sioux Falls, South Dakota, emphasizing political science and economics. The following year he studied as a Rockefeller fellow at the Harvard Divinity School in Cambridge, Massachusetts.


    Yuichiro Morimoto is the President of Enplas America and Chief R&D division of Enplas Corporation. Yuichiro leads multiple global teams in the SF Bay Area, New York, Cambridge UK, Haifa Israel, and Tokyo to generate new businesses through venture investment, M&A, and organic R&D, by leveraging Enplas’ ultra-precision polymer manufacturing technologies. The teams cover various industries such as in-vitro diagnosis, medical devices, agriculture, optical components, automotive, and consumer electronics. His teams provide hands-on support to its portfolio of companies through its many years of expertise in precision manufacturing, global supplier management, sales process and distribution, business development, and fundraising. Yuichiro is on the Board of Directors for many of the companies Enplas receiving Enplas investment. Prior to joining Enplas, Yuichiro worked for McKinsey for 10 years supporting Japanese and global companies in medical device, pharmaceutical, automotive, and consumer electronics industries. Yuichiro holds a PhD in nuclear engineering from the University of Tokyo. 


    General Dennis J. Reimer (U.S. Army, Ret.) served over 37 years in the U. S. Army. In 1995, General Reimer became the 33rd Chief of Staff, U.S. Army, and a member of the Joint Chiefs of Staff. Prior to that, he was the Commanding General of the United States Army, Forces Command, Fort McPherson, Georgia. During his military career he served in a variety of other joint and combined assignments, as well as two combat tours in Vietnam. He also served in Korea as the Chief of Staff, Combined Field Army and Assistant Chief of Staff for Operations and Training, Republic of Korea/United States Combined Forces Command.  After his retirement from the army in 1999 General Reimer became the first Director of the National Memorial Institute for the Prevention of Terrorism in Oklahoma City, an organization dedicated to preventing terrorism in the United States. In 2005 he returned to Washington D.C. to take a position with DFI, a national security consulting firm. DFI was acquired by a British firm, Detica, and General Reimer remained with the new organization for about a year.  He served as the President of Army Emergency Relief from 2009 until 2019 and is currently the Chairman of the Board of the American Armed Forces Mutual Aid Association.  He also is a Mutual of America board member and a member of the Thayer Leadership Team at West Point. 

    Stay in the know on INT technology!
    Get started here!